Showing results (2341-2350 of 2,503) with videos related to

Sort By:
Pageof 251
Nature Medicine|May 10, 2000
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivoR Atreya, J Mudter, S Finotto, et al.
Circulation|May 29, 2008
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery diseaseMark Y Chan, Mauricio G Cohen, Christopher K Dyke, et al.
JCO Precision Oncology|September 11, 2020
Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic MelanomaRenáta Váraljai, Kilian Wistuba-Hamprecht, Teofila Seremet, et al.
Journal of the American College of Cardiology|February 25, 2014
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trialKenneth W Mahaffey, Claes Held, Daniel M Wojdyla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survivalKelly G Paulson, Jayasri G Iyer, Andrew R Tegeder, et al.
Nature Genetics|July 22, 2011
Recombination rates in admixed individuals identified by ancestry-based inferenceDaniel Wegmann, Darren E Kessner, Krishna R Veeramah, et al.
BMC Genetics|May 24, 2011
The impact of FADS genetic variants on ω6 polyunsaturated fatty acid metabolism in African AmericansRasika A Mathias, Susan Sergeant, Ingo Ruczinski, et al.
Lancet (London, England)|May 18, 2020
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialLisa Zimmer, Elisabeth Livingstone, Jessica C Hassel, et al.
Thrombosis and Haemostasis|January 10, 2014
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic SubstudyRobert F Storey, Jayaprakash Kotha, Susan S Smyth, et al.
The Journal of Pathology|July 25, 2024
Analyses of combined Merkel cell carcinomas with neuroblastic components suggests that loss of T antigen expression in Merkel cell carcinoma may result in cell cycle arrest and neuroblastic transdifferentiationThibault Kervarrec, Silke Appenzeller, Susanne Gramlich, et al.
Pageof 251